RIOK2 and glioblastoma: To date, RIOK2 has been found to be highly expressed only in non-small cell lung cancer (Liu et al., 2016; Liu et al., 2018), prostate cancer (Read et al., 2013), glioblastoma (Liu et al., 2016), acute myeloid leukemia (Messling et al., 2021), and hepatocellular carcinoma cells (Delman et al., 2019).